Pimagedine aminoguanidine: Phase III data

Final data from ALTN's 690-patient North American ACTION I trial showed that pimagedine treatment reduced total urinary protein excretion (p<0.001 versus placebo) and reduced the number of patients with a doubling of creatinine, a measure of kidney function (p=0.099 versus placebo). A total of 10 percent of pimagedine-treated patients experienced progression of retinopathy compared to 16 percent of placebo-treated patients (p=0.03). Side effects included a transient flu-like syndrome, anemia and induction of autoantibodies. ...